TipRanks
ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF

Compare ALK-abello (AKBLF) vs. Competitors

16 Followers

Comparison Results

Name
Price
Market Cap
P/E Ratio
Yearly Gain
Analyst Consensus
Analyst Price Target
Compare
Top Analysts' Price Target
Smart Score
Follow
ALK-abello
$32.72
$7.59B
37.28
2.95%
―
Inovio Pharmaceuticals
$1.29
$118.91M
-0.96
-56.60%
2 Buy
1 Hold
0 Sell
Moderate Buy
Aclaris Therapeutics
$6.19
$563.77M
-6.59
96.41%
5 Buy
0 Hold
0 Sell
Strong Buy
Emergent Biosolutions
$5.64
$361.99M
-2.03
-29.68%
1 Buy
0 Hold
1 Sell
Hold
Novartis
$159.98
$262.78B
21.78
9.68%
3 Buy
3 Hold
1 Sell
Moderate Buy
Bristol-Myers Squibb
$64.72
$120.77B
13.03
32.32%
8 Buy
12 Hold
1 Sell
Moderate Buy

Performance Comparison

Ticker
Company Name
Price
Change
% Change
AKBLF
ALK-abello
34.03
1.28
3.90%
DVAX
―
―
―
―
INO
Inovio Pharmaceuticals
1.15
-1.32
-53.44%
ACRS
Aclaris Therapeutics
3.83
1.92
100.52%
EBS
Emergent Biosolutions
7.06
-2.24
-24.09%
NVS
Novartis
143.75
17.11
13.51%
BMY
Bristol-Myers Squibb
59.12
17.43
41.83%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts